Literature DB >> 26758437

Association of serum KL-6 levels with interstitial lung disease in patients with connective tissue disease: a cross-sectional study.

Ekin Oktay Oguz1, Orhan Kucuksahin2, Murat Turgay2, Mustafa Turgut Yildizgoren3, Askin Ates2, Nalan Demir4, Ozlem Ozdemir Kumbasar4, Gulay Kinikli2, Nursen Duzgun2.   

Abstract

It was aimed to evaluate KL-6 glycoprotein levels to determine if it may be a diagnostic marker for the connective tissue diseases (CTDs) predicting CTD-related interstitial lung diseases (ILDs) (CTD-ILD) development and to examine if there was a difference between patients and healthy controls. The study included 113 patients with CTD (45 CTD without lung involvement, 68 CTD-ILD) and 45 healthy control subjects. KL-6 glycoprotein levels were analyzed with ELISA in patients and the control group. The relationship between KL-6 glycoprotein levels and CTD-ILD was assessed. In the comparison of all the groups in the study, significantly higher levels of KL-6 were determined in the CTD-ILD group than in either the CTD without pulmonary involvement group or the healthy control group (p < 0.008 and p < 0.001, respectively). There was no statistically significant difference between the KL-6 levels in the healthy control group and the CTD without pulmonary involvement group (p = 0.289). The KL-6 levels did not differ significantly according to the connective tissue diseases in the diagnostic groups (systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis, mixed connective tissue disease, scleroderma, polymyositis/ dermatomyositis). In the healthy control group, there was a statistically significant difference between KL-6 levels in smokers and non-smokers. Smokers had significantly higher serum KL-6 levels compared with non-smokers (p < 0.05). There was no statistically significant difference between smoking status (pack-year) and serum KL-6 levels. There was no statistically significant correlation between serum KL-6 levels and time since diagnosis of CTD and CTD-ILD. The level of KL-6 as a predictive factor could be used to identify the clinical development of ILD before it is detected on imaging modality. Further prospective clinical studies are needed to define whether levels of KL-6 might have prognostic value or might predict progressive ILD.

Entities:  

Keywords:  Connective tissue disease; Connective tissue disease-related interstitial lung disease; Interstitial lung disease; Krebs von den Lungen-6

Mesh:

Substances:

Year:  2016        PMID: 26758437     DOI: 10.1007/s10067-015-3167-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  16 in total

1.  Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Authors:  K Yamane; H Ihn; M Kubo; N Yazawa; K Kikuchi; Y Soma; K Tamaki
Journal:  J Rheumatol       Date:  2000-04       Impact factor: 4.666

2.  Serum KL-6 levels in patients with pulmonary complications after allogeneic bone marrow transplantation.

Authors:  T Ashida; M Higashishiba; Y Sumimoto; T Sano; H Miyazato; T Shimada; J Miyatake; K Kawanishi; Y Tatsumi; A Kanamaru
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

3.  Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.

Authors:  K Yanaba; M Hasegawa; Y Hamaguchi; M Fujimoto; K Takehara; S Sato
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

4.  Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Authors:  Hiroshi Ohnishi; Akihito Yokoyama; Keiichi Kondo; Hironobu Hamada; Masahiro Abe; Kazutaka Nishimura; Kunio Hiwada; Nobuoki Kohno
Journal:  Am J Respir Crit Care Med       Date:  2002-02-01       Impact factor: 21.405

5.  Serum Krebs von den Lungen-6 level as a diagnostic biomarker for interstitial lung disease in Chinese patients.

Authors:  Yang Hu; Liu-Sheng Wang; Yue-Ping Jin; Shan-Shan Du; Yu-Kui Du; Xian He; Dong Weng; Ying Zhou; Qiu-Hong Li; Li Shen; Fen Zhang; Yi-Liang Su; Xiao-Li Sun; Jing-Jing Ding; Wen-Hui Zhang; Hou-Rong Cai; Hua-Ping Dai; Jing-Hong Dai; Hui-Ping Li
Journal:  Clin Respir J       Date:  2015-07-07       Impact factor: 2.570

Review 6.  Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis.

Authors:  N Kohno
Journal:  J Med Invest       Date:  1999-08

7.  KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts.

Authors:  Shinichiro Ohshimo; Akihito Yokoyama; Noboru Hattori; Nobuhisa Ishikawa; Yutaka Hirasawa; Nobuoki Kohno
Journal:  Biochem Biophys Res Commun       Date:  2005-11-02       Impact factor: 3.575

Review 8.  Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.

Authors:  Nobuhisa Ishikawa; Noboru Hattori; Akihito Yokoyama; Nobuoki Kohno
Journal:  Respir Investig       Date:  2012-03-08

Review 9.  Connective tissue disease-associated lung disease.

Authors:  Amy L Olson; Kevin K Brown; Aryeh Fischer
Journal:  Immunol Allergy Clin North Am       Date:  2012-11       Impact factor: 3.479

Review 10.  Assessment and management of connective tissue disease-associated interstitial lung disease.

Authors:  Aryeh Fischer; Sandra Chartrand
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2015-06-22       Impact factor: 0.670

View more
  18 in total

1.  Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.

Authors:  Yukai Wang; Shaoqi Chen; Zhangzhang Lin; Jianqun Lin; Xuezhen Xie; Qisheng Lin; Guangzhou Du; Xiufeng Huang; Marco Matucci-Cerinic; Daniel E Furst
Journal:  Clin Rheumatol       Date:  2019-02-11       Impact factor: 2.980

Review 2.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

3.  Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis.

Authors:  Guangbo Chen; Gail H Deutsch; Grant S Schulert; Hong Zheng; SoRi Jang; Bruce Trapnell; Pui Y Lee; Claudia Macaubas; Katherine Ho; Corinne Schneider; Vivian E Saper; Adriana Almeida de Jesus; Mark A Krasnow; Alexei Grom; Raphaela Goldbach-Mansky; Purvesh Khatri; Elizabeth D Mellins; Scott W Canna
Journal:  Arthritis Rheumatol       Date:  2022-05-31       Impact factor: 15.483

4.  Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.

Authors:  Audrey Benyamine; Xavier Heim; Noémie Resseguier; Daniel Bertin; Carine Gomez; Mikaël Ebbo; Jean-Robert Harlé; Gilles Kaplanski; Pascal Rossi; Nathalie Bardin; Brigitte Granel
Journal:  Rheumatol Int       Date:  2018-02-17       Impact factor: 2.631

5.  Tumor-Associated Antigens in Rheumatoid Arthritis Interstitial Lung Disease or Malignancy?

Authors:  Gökhan Sargin; Reyhan Köse; Taşkın Şentürk
Journal:  Arch Rheumatol       Date:  2018-01-29       Impact factor: 1.472

6.  Diagnostic value of KL-6 in idiopathic interstitial pneumonia.

Authors:  Peiyan Zheng; Xiaoqing Liu; Huimin Huang; Zijun Guo; Ge Wu; Haisheng Hu; Chuanxu Cai; Wenting Luo; Nili Wei; Qian Han; Baoqing Sun
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

7.  Interstitial lung disease with myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis in elderly patients.

Authors:  Koichi Yamaguchi; Aya Yamaguchi; Miki Itai; Yuji Onuki; Yuki Shin; Shogo Uno; Chiharu Hanazato; Kohei Taguchi; Kazue Umetsu; Masaki Aikawa; Shunichi Kouno; Masao Takemura; Kenichiro Hara; Shinsuke Motegi; Mayuko Tsukida; Fumie Ota; Yoshito Tsukada; Mitsuru Motegi; Masao Nakasatomi; Toru Sakairi; Hidekazu Ikeuchi; Yoriaki Kaneko; Keiju Hiromura; Toshitaka Maeno
Journal:  Rheumatol Int       Date:  2021-05-30       Impact factor: 2.631

Review 8.  Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.

Authors:  Olivier Bonhomme; Béatrice André; Fanny Gester; Dominique de Seny; Catherine Moermans; Ingrid Struman; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Rheumatology (Oxford)       Date:  2019-09-01       Impact factor: 7.580

9.  Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Hongying Zhang; Lizhou Chen; Luling Wu; Jinbao Huang; Hongyan Li; Xinhang Wang; Heng Weng
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

10.  Correlation Between Serum Tumor Marker Levels and Connective Tissue Disease-Related Interstitial Lung Disease.

Authors:  Yunqi Bao; Wei Zhang; Dandan Shi; Weili Bai; Dongdong He; Dan Wang
Journal:  Int J Gen Med       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.